Compare Novo Nordisk A/S (NVO) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Zimmer Biomet Holdings Inc — how do they compare? Novo Nordisk A/S trades at $49.32 (market cap $220.53B), while Zimmer Biomet Holdings Inc trades at $90.03 (market cap $17.36B). The key difference: Novo Nordisk A/S is far larger — about 12.7× Zimmer Biomet Holdings Inc's market cap, and Novo Nordisk A/S pays the higher dividend (3.63%). Which is the better fit depends on your goals.
| NVO | ZBH | |
|---|---|---|
Market Cap | $220.53B | $17.36B |
Sector | Health | Health |
52-Week High | $71.70 | $107.71 |
52-Week Low | $35.29 | $79.58 |
Enterprise Value | $239.49B | $24.40B |
Dividend Yield | 3.63% | 1.07% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
